Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance

Hideto Kameda, Keiichiro Nishida, Toshihiro Nannki, Akira Watanabe, Yukiya Oshima, Shigaki Momohara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To evaluate the safety and effectiveness of certolizumab pegol (CZP) in a real-world setting among Japanese patients with rheumatoid arthritis. Methods: Post-marketing surveillance data from 2,579 patients treated with CZP were analyzed. Adverse events (AEs) observed during the 24-week CZP treatment period were recorded. Disease activity was evaluated using DAS28-ESR and DAS28-CRP at baseline, Week 12, Week 24, or at withdrawal. Results: The total period of exposure to CZP was 1313.8 patient-years (PY). AEs were reported in 658 (25.5%) patients, at an event rate (ER) of 73.68/100 PY. The most frequent serious AEs were pneumonia, herpes zoster, and interstitial lung disease, at ER per 100 PY of 2.06, 1.29, and 1.22, respectively. Mean disease activity scores at baseline, as measured by DAS28-ESR and DAS28-CRP, were 4.77 ± 1.34 and 4.21 ± 1.27, respectively. Mean changes from baseline at the last observation were –1.29 ± 1.46 and –1.30 ± 1.42, respectively. EULAR good or moderate responses were achieved in 65% of patients. Longer disease duration, prior biologics use, and treatment without MTX co-therapy were associated with EULAR no response. Conclusion: In this interim analysis, no new safety signals were observed. Clinical response to CZP was observed in approximately two thirds of patients.

Original languageEnglish
Pages (from-to)196-205
Number of pages10
JournalJapanese Journal of Clinical Immunology
Volume40
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Marketing
Rheumatoid Arthritis
Safety
Certolizumab Pegol
Interstitial Lung Diseases
Herpes Zoster
Biological Products
Pneumonia
Therapeutics
Observation

Keywords

  • Certolizumab pegol
  • Effectiveness
  • Post-marketing surveillance
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis : Interim analysis of post-marketing surveillance. / Kameda, Hideto; Nishida, Keiichiro; Nannki, Toshihiro; Watanabe, Akira; Oshima, Yukiya; Momohara, Shigaki.

In: Japanese Journal of Clinical Immunology, Vol. 40, No. 3, 2017, p. 196-205.

Research output: Contribution to journalArticle

Kameda, Hideto ; Nishida, Keiichiro ; Nannki, Toshihiro ; Watanabe, Akira ; Oshima, Yukiya ; Momohara, Shigaki. / Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis : Interim analysis of post-marketing surveillance. In: Japanese Journal of Clinical Immunology. 2017 ; Vol. 40, No. 3. pp. 196-205.
@article{f2e247c10ae142a5ba695b44427f5059,
title = "Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance",
abstract = "Objective: To evaluate the safety and effectiveness of certolizumab pegol (CZP) in a real-world setting among Japanese patients with rheumatoid arthritis. Methods: Post-marketing surveillance data from 2,579 patients treated with CZP were analyzed. Adverse events (AEs) observed during the 24-week CZP treatment period were recorded. Disease activity was evaluated using DAS28-ESR and DAS28-CRP at baseline, Week 12, Week 24, or at withdrawal. Results: The total period of exposure to CZP was 1313.8 patient-years (PY). AEs were reported in 658 (25.5{\%}) patients, at an event rate (ER) of 73.68/100 PY. The most frequent serious AEs were pneumonia, herpes zoster, and interstitial lung disease, at ER per 100 PY of 2.06, 1.29, and 1.22, respectively. Mean disease activity scores at baseline, as measured by DAS28-ESR and DAS28-CRP, were 4.77 ± 1.34 and 4.21 ± 1.27, respectively. Mean changes from baseline at the last observation were –1.29 ± 1.46 and –1.30 ± 1.42, respectively. EULAR good or moderate responses were achieved in 65{\%} of patients. Longer disease duration, prior biologics use, and treatment without MTX co-therapy were associated with EULAR no response. Conclusion: In this interim analysis, no new safety signals were observed. Clinical response to CZP was observed in approximately two thirds of patients.",
keywords = "Certolizumab pegol, Effectiveness, Post-marketing surveillance, Rheumatoid arthritis, Safety",
author = "Hideto Kameda and Keiichiro Nishida and Toshihiro Nannki and Akira Watanabe and Yukiya Oshima and Shigaki Momohara",
year = "2017",
doi = "10.2177/jsci.40.196",
language = "English",
volume = "40",
pages = "196--205",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis

T2 - Interim analysis of post-marketing surveillance

AU - Kameda, Hideto

AU - Nishida, Keiichiro

AU - Nannki, Toshihiro

AU - Watanabe, Akira

AU - Oshima, Yukiya

AU - Momohara, Shigaki

PY - 2017

Y1 - 2017

N2 - Objective: To evaluate the safety and effectiveness of certolizumab pegol (CZP) in a real-world setting among Japanese patients with rheumatoid arthritis. Methods: Post-marketing surveillance data from 2,579 patients treated with CZP were analyzed. Adverse events (AEs) observed during the 24-week CZP treatment period were recorded. Disease activity was evaluated using DAS28-ESR and DAS28-CRP at baseline, Week 12, Week 24, or at withdrawal. Results: The total period of exposure to CZP was 1313.8 patient-years (PY). AEs were reported in 658 (25.5%) patients, at an event rate (ER) of 73.68/100 PY. The most frequent serious AEs were pneumonia, herpes zoster, and interstitial lung disease, at ER per 100 PY of 2.06, 1.29, and 1.22, respectively. Mean disease activity scores at baseline, as measured by DAS28-ESR and DAS28-CRP, were 4.77 ± 1.34 and 4.21 ± 1.27, respectively. Mean changes from baseline at the last observation were –1.29 ± 1.46 and –1.30 ± 1.42, respectively. EULAR good or moderate responses were achieved in 65% of patients. Longer disease duration, prior biologics use, and treatment without MTX co-therapy were associated with EULAR no response. Conclusion: In this interim analysis, no new safety signals were observed. Clinical response to CZP was observed in approximately two thirds of patients.

AB - Objective: To evaluate the safety and effectiveness of certolizumab pegol (CZP) in a real-world setting among Japanese patients with rheumatoid arthritis. Methods: Post-marketing surveillance data from 2,579 patients treated with CZP were analyzed. Adverse events (AEs) observed during the 24-week CZP treatment period were recorded. Disease activity was evaluated using DAS28-ESR and DAS28-CRP at baseline, Week 12, Week 24, or at withdrawal. Results: The total period of exposure to CZP was 1313.8 patient-years (PY). AEs were reported in 658 (25.5%) patients, at an event rate (ER) of 73.68/100 PY. The most frequent serious AEs were pneumonia, herpes zoster, and interstitial lung disease, at ER per 100 PY of 2.06, 1.29, and 1.22, respectively. Mean disease activity scores at baseline, as measured by DAS28-ESR and DAS28-CRP, were 4.77 ± 1.34 and 4.21 ± 1.27, respectively. Mean changes from baseline at the last observation were –1.29 ± 1.46 and –1.30 ± 1.42, respectively. EULAR good or moderate responses were achieved in 65% of patients. Longer disease duration, prior biologics use, and treatment without MTX co-therapy were associated with EULAR no response. Conclusion: In this interim analysis, no new safety signals were observed. Clinical response to CZP was observed in approximately two thirds of patients.

KW - Certolizumab pegol

KW - Effectiveness

KW - Post-marketing surveillance

KW - Rheumatoid arthritis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85026359495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026359495&partnerID=8YFLogxK

U2 - 10.2177/jsci.40.196

DO - 10.2177/jsci.40.196

M3 - Article

C2 - 28747607

AN - SCOPUS:85026359495

VL - 40

SP - 196

EP - 205

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 3

ER -